Chronic Hepatitis News

SAN FRANCISCO — Despite continued drug use, hepatitis C reinfection rarely occurred in a cohort of patients with HCV who received opioid agonist therapy and were treated for HCV, according to findings presented at The Liver Meeting 2018.

SAN FRANCISCO — Universal screening of pregnant women at risk for hepatitis C was more efficient and cost-effective compared with risk-based screening, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Mavyret was highly effective and well-tolerated in patients with chronic hepatitis C genotype 1 who had experience with a combination of Sovaldi, NS5A inhibitor and ribavirin, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Starting this weekend, Healio Gastroenterology and Liver Disease will provide live coverage from The Liver Meeting 2018.

AbbVie announced a new interactive online resource, MappingHepC.com, that features national and state-level data on hepatitis C screening, diagnosis and treatment, according to a press release.

Hepatocellular carcinoma recurrence rates and patterns did not differ between patients who underwent interferon-based antiviral therapy for hepatitis C and those who received direct-acting antiviral therapy, according to a recently published study.

Data from Australia’s annual bio-behavioral surveillance of people who inject drugs attending needle syringe programs between 2015 and 2017 showed a significant increase in hepatitis C treatment uptake and decrease in viremic prevalence, especially among older patients and those with a history of opioid substitution therapy.

Significant incidents of hepatitis A outbreaks occurred through direct person-to-person transmission among drug users and homeless individuals during 2017, according to a report from the CDC.

Results from a phase 2 study of Lambda for the treatment of hepatitis D showed a decline of HDV RNA in more than half of treated patients, according to a press release from Eiger BioPharmaceuticals.

TARGET PharmaSolutions initiated patient enrollment for an observational study of patients with chronic hepatitis B to gather real-world data and advance the understanding of HBV, according to a press release.